Making Ketamine Work in the Long Run by Early, Terrence S.
International Journal of
Transpersonal Studies
Volume 33 | Issue 2 Article 9
7-1-2014
Making Ketamine Work in the Long Run
Terrence S. Early
Interventional Psychiatry Associates
Follow this and additional works at: https://digitalcommons.ciis.edu/ijts-transpersonalstudies
Part of the Philosophy Commons, Psychiatry and Psychology Commons, and the Religion
Commons
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
This Special Topic Article is brought to you for free and open access by the Journals and Newsletters at Digital Commons @ CIIS. It has been accepted
for inclusion in International Journal of Transpersonal Studies by an authorized administrator of Digital Commons @ CIIS. For more information,
please contact digitalcommons@ciis.edu.
Recommended Citation
Early, T. S. (2014). Early, T. S. (2014). Making ketamine work in the long run. International Journal of Transpersonal Studies, 33(2),
141-150.. International Journal of Transpersonal Studies, 33 (2). http://dx.doi.org/10.24972/ijts.2014.33.2.141
International Journal of Transpersonal Studies 141Making Ketamine Work
Making Ketamine Work in the Long Run 
Treatments such as ketamine psychotherapy face substantial financial and regulatory obstacles 
to dissemination into widespread use.  Newly patented medications are able to generate enough 
capital to pay for studies required for FDA approval, personnel to apply for coverage on insurance 
plans, and marketing to establish a successful launch.  Ketamine is an older drug with considerable 
evidence of efficacy for treatment resistant depression, and almost 50 years of data concerning 
safety as an anesthetic agent.  However, it can no longer be patented, so there is no incentive for 
pharmaceutical companies to help get it into widespread use.  In this paper we discuss some of 
the complex issues surrounding use of ketamine in the outpatient setting and share information 
and practice pearls that have been gathered through communication with other practitioners and 
through direct experience with over 1000 treatments involving 120 patients in the last eight years. 
The safety and appropriateness of intramuscular ketamine treatment in the outpatient psychiatric 
office is discussed.  We hope to help proponents of effective mental health interventions navigate 
the actual and potential challenges involved in safe application of this treatment option outside of 
hospital-based programs.   
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Ketamine shows considerable efficacy for rapid symptom relief in treatment resistant depression, as well as an exceptional safety record as an 
anesthetic agent with over nearly 50 years of clinical use. 
Based on this evidence, ketamine appears to be a safe and 
effective treatment for depression in outpatient settings. 
At the same time, there are financial and regulatory 
obstacles to dissemination of ketamine into widespread 
use as a psychoactive medication. Newly patented 
medications that show promise are  typically able to 
attract capital investment to pay for studies required by 
the Food and Drug Administration (FDA) in order to 
be approved for a specific use that will then be covered 
by insurance plans. However, since ketamine can no 
longer be patented, there is little financial incentive for 
pharmaceutical for  psychiatric  applications. Given the 
great need for effective new antidepressant strategies, and 
the regulatory situation of ketamine treatment for mood 
disorders, the dissemination of information regarding 
its promising efficacy will necessarily proceed through 
channels that are professional rather than commercial.  
 This report is based on the experience of the 
author and a colleague (Jeffrey Becker) who have had 
direct experience with over 1000 ketamine treatments 
conducted with 120 patients over the past eight years; 
in addition, the author is in communication with other 
practitioners involved in ketamine treatment. Based 
on this clinical experience, the current paper reports 
on the actual and potential challenges involved in safe 
application of intramuscular ketamine treatment for 
psychological conditions such as depression in outpatient 
settings.
 Early’s interest in ketamine for depression began 
after studying another anesthetic treatment approach 
that never became mainstream—halothane isoelectric 
therapy, using sevoflurane. Langer, Neumark, Koinig, 
Graf, and Schoenbeck (1985) originally reported that 
a related anesthetic agent, isoflurane, had a robust 
antidepressant effect comparable to electroconvulsive 
therapy (ECT) in an open-label trial.  These results were 
later replicated in a double-blinded trial (Langer et al., 
1995).  Early found similar results with an open label 
trial of sevoflurane therapy and a blinded comparison 
to ECT (Early et al., unpublished results). Langer’s 
isoflurane results were recently replicated by Weeks et 
al. (2013). Halothane isoelectric therapy produces a 
period of isoelectric electroencephalography (EEG) 
similar to the state that follows an ECT-induced seizure, 
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but without seizure-related cognitive side effects. Early 
found it impossible to disseminate the technique, since 
there was no mechanism to pay for anesthesiology and 
hospital time to provide the treatment and no way to 
obtain insurance coverage. Ketamine offered a less 
expensive and less invasive alternative, and Early began 
using it in 2007. 
 Becker examined the potential of ketamine on 
depression in medical school and psychiatric residents at 
UCLA.  While looking at the NMDA receptor related 
neurological substrates of transcendent experience it 
became clear that ketamine might provide relief from 
depression.  Multiple clinical studies now confirm this 
(Mathews & Zarate, 2013).
A Mandate for New Treatment Options 
Ketamine represents the first new receptor-based treatment for depression in decades and has the 
potential to provide profound relief from great suffering. 
In contrast with monoamine oxidase inhibitors and 
tricyclic antidepressants that typically take weeks or 
months to reach full effectiveness—and too often are 
not effective at all—ketamine appears to provide rapid 
relief from symptoms of depression, even in treatment-
resistant cases (Zarate et al., 2006; Diazgranados et 
al., 2010). Ketamine may represent a breakthrough 
in the broader treatment of depression by offering 
a novel pharmacological strategy focused on the 
glutamatergic system, which may be more central to the 
neurobiological mechanisms of mood disorders than the 
serotonergic, noradrenergic, and dopaminergic systems 
typically targeted in conventional pharmacological 
treatments for mood disorder (Sanacora, Zarate, Krystal, 
& Manji, 2008). There is evidence that ketamine 
impacts the N-methyl-D-aspartate (NMDA) receptor 
complex, which may itself mediate the delayed relief in 
conventional treatment strategies; targeting this system 
directly may represent a significantly more efficient 
approach to the treatment of depression, and of mood 
disorders more broadly, with a potentially large impact 
on public health (Zarate et al., 2010).  
 The use of medications as psychotherapeutic 
adjuncts has a long history in psychiatry (Kolb, 1985). 
Barbiturate-facilitated psychotherapy, introduced by 
Blackwenn (1930), was practiced for over 80 years to 
treat conversion symptoms and traumatic war neurosis 
or PTSD. The amytal and pentothal interviews were 
developed later, along with other forms of drug-
facilitated psychotherapy (Grinker & Speigel, 1945; 
Horsely, 1943; Lindemann, 1932). Sometimes called 
abreactive psychotherapy, this approach was reported 
to produce rapid relief of classic symptoms such as 
flashbacks, nightmares, hypervigilence, and autonomic 
hyper-reactivity (Hoch, 1946). Shovrin and Sargant 
(1947) introduced an excitatory abreactive therapy using 
ether and a variety of other agents, which later were used 
to facilitate learning during psychotherapy (Sargant & 
Slater, 1972).  
Clearly the psychological effects that occur 
with ketamine use as an antidepressant treatment touch 
similar themes. While these older treatment techniques 
were in danger of becoming a simple footnote in 
psychiatric history, the improved safety and efficacy of 
ketamine may eventually provide PTSD patients with 
a viable treatment model in this mode. Indeed, Feder 
et al. (2014) recently reported a robust effect on core 
symptoms of PTSD with ketamine treatment.
 However, perception of safety is likely to be 
one of the largest challenges to broader acceptance of 
ketamine’s role in psychiatry and the adoption of this 
treatment within outpatient psychiatric offices.  Despite 
the fact that the outpatient psychiatric office is likely to 
be the most efficient and effective in delivering treatment 
to those in need, currently the majority of participating 
practitioners are anesthesiologists or are at hospital-
based programs. The author hopes to clarify issues that 
will allow broader adoption of this effective treatment 
option in outpatient psychiatric clinics. Fear regarding 
safety, both founded and often unfounded, should be 
balanced by clinical evidence and an awareness of the 
immense need for effective treatment delivery.   
Safety of Low-Dose Ketamine Therapy 
Intramuscular ketamine is generally considered safe at subanesthetic doses, even in non-medical settings. 
When used to induce general anesthesia, ketamine is 
generally administered at a dose range of 3-8 mg/kg 
IM or 1-4.5 mg/kg IV. The usual maintenance dose 
for ketamine is an IV bolus of 0.1-0.5 mg/kg/minute. 
Ketamine is often combined with other anesthetic 
agents (such as propofol), and the dose is typically less in 
this situation.  Even at doses used for general anesthesia, 
ketamine is associated with normal pharyngeal-laryngeal 
reflexes, and usually cardiovascular and respiratory 
stimulation, though there may occasionally be a transient 
and minimal respiratory depression. In the low-dose 
range 0.5-1 mg/kg, patients experience conscious sedation, 
which means they remember the experience and respond 
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to stimuli during the session. The physiologic effects of 
subanesthetic ketamine provide a large margin of safety 
in the treatment of depression through preservation of 
responsivity to the practitioner, cardiac stimulation, and 
maintanence of respiratory function and the gag reflex 
(Hass & Harper, 1992).
 Early and Becker have found use in the outpatient 
setting to be remarkably free of adverse effects. Nausea 
and occasional vomiting are the most common negative 
effects, which are minimized by fasting 4-6 hours prior 
to treatment or through the use of ondansetron. Anxiety 
upon arrival at a session is common and is managed 
through pretreatment discussion, clonidine and/or, 
if needed, oral lorazepam. Blood pressure increases 
of 5-10 mm/hg diastolic and 5-15 mm/hg systolic are 
routine while heart rate increases of 10-20 bpm are seen 
less commonly. We have not seen laryngospasm, severe 
hypertension, respiratory distress, or severe agitation in 
any of our cases. Our experience is consistent with the 
experience of other clinicians with whom we consult and 
with existing research.  
 Ketamine’s large safety margin provides 
reassurance in settings where anesthesiologists and 
monitoring are not available, such as the battlefield, 
veterinary medicine, dentistry, and pediatric anesthesia. 
O’Hara, Ganeshalingam, Gerrish, and Richardson 
(2014) reported no adverse cardiac or respiratory events 
after 131 sedation procedures by nursing with oral 
ketamine, which is known to be more unpredictable 
than IM or IV routes. In this study, an anesthesiology 
consult was only required to further deepen sedation 
or deal with excessive sedation. The National Clinical 
Guideline Centre recommends that anesthesiology be 
present only when ketamine is administered with opiates 
(National Institute for Health and Care Excellence 
[NICE], 2010). Even in full anesthesia, reflecting doses 
up to 10 times those used for depression (e.g., 2 mg/kg IV 
to 5 mg/kg IM), ketamine is remarkably safe. A review 
of over 70,000 published anesthesia cases reported only 
one ketamine-related fatality occurring in a seriously 
medically compromised individual (Strayer & Nelson, 
2008).  
 Given the confusion between full anesthesia 
and conscious sedation a few issues do deserve further 
clarification. 
Respiratory Drive
Bourke, Malit, and Smith  (1987) reported 
minimal changes in respiratory drive with low-dose 
IV ketamine and a 5% drop in minute ventilation (l/
min) at 1.08 mg/kg. Mankikian, Cantineou, Sortene, 
Clergue, and Viars (1986) reported no significant 
change in respiratory functional residual capacity and 
minute ventilation or tidal volume after full anesthetic 
induction with 3 mg/kg. Morel, Forster, and Gemperle 
(1986) reported increased respiratory drive, stable 
arterial oxygen saturation, and end-tidal carbon dioxide 
concentration with 1 mg/kg delivered IV. In addition, 
bronchodilatory effects of ketamine, likely second to 
circulating catecholamines, have been observed in canine 
models. Ketamine has been used successfully in pediatric 
status asthmaticus to facilitate intubation (Reich & 
Silvay, 1989). While salivary secretions increase with 
ketamine-induced full anesthesia this does not appear to 
be a problem in conscious sedation due to intact swallow 
reflexes and the vastly lower doses involved. In short, 
respiratory drive remains intact with low dose (and even 
high dose) ketamine (Hass & Harper, 1992). 
Blood Pressure and Intercranial Pressure
It is understood that ketamine can increase 
heart rate and arterial pressure (Hass & Harper, 1992) at 
least partially through increases in free norepinephrine 
(Zsigmond, Kelsch, & Kothary, 1973). Hypertension 
should therefore be well controlled prior to treatment. 
Mild increases in intracranial pressure have been noted 
with ketamine, and Haas and Harper (1992) saw this as 
a contraindication for use in vulnerable individuals. 
Emergence Reaction
Ketamine’s psychological effects are often 
reported in anesthesia and surgery research as an adverse 
effect. While these effects may actually be inherent to 
antidepressant effects, ketamine and other dissociative 
drugs have been reported to exacerbate psychotic 
symptoms in schizophrenia. While Carpenter (1999) 
reported a lack of significant negative effects after 
administration to 12 subjects with stable schizophrenia, 
ketamine is not likely to be indicated for treatment in 
cases involving primary psychosis.
Screening and Contraindications
Given physical safety considerations and the unique psychological effects of ketamine, treatment with 
minimal monitoring is relatively contraindicated in the 




Other impaired cardiac status
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Severe Chronic Obstructive Pulmonary    
     Disease (COPD)
Severe Obesity
Increased intracranial or cerebrospinal (CSF) 
     pressure 
Schizophrenia and Schizoaffective Disorder
Severe or Primitive Personality Disorders 
Patient Selection and Evaluation
During an initial evaluation, psychiatric and medical history is reviewed along with lab work, past 
treatment history, and history of substance abuse. Issues 
relating to cardiac and pulmonary history, prior adverse 
response to anesthesia, evidence of sleep apnea, and 
history of primary psychosis are assessed. The patient is 
considered a candidate for a ketamine session if they have 
already failed multiple antidepressant trials and specific 
contraindications do not exist. If the patient is severely 
ill or suicidal, ketamine may be the treatment option 
most likely to produce rapid, if temporary remission. 
Consent for Treatment
 A thorough informed consent process educates 
patients to the psychological effects of treatment and 
addresses the expectations and questions of the patient 
and their family. Topics for discussion include acute and 
residual side effects, potential risks and benefits, the off-
label nature of the treatment, and the research supporting 
ketamine’s use in the treatment of depression. The scope 
and duration of potential positive effects should be 
discussed with every patient. Discussion regarding the 
frequency and number of treatments required can be 
informed by the naturalistic outcomes seen in ECT, in 
that some patients respond after relatively few treatments 
while others require a longer course of treatment.
 The consent process helps to set realistic 
but positive expectations, which may be an essential 
element to success. With proper control of the physical 
environment (e.g., dim light, music, reclining position) 
the treatment experience is usually described by patients 
as meaningful and positive. Psychotherapy is an essential 
part of the process of recovery and is recommended 
to every patient receiving ketamine treatment. Our 
considerations regarding therapy are beyond the scope 
of this paper, however, and will be provided in another 
forum (see Becker, this issue, p.  ___).  
The Ketamine Treatment 
Patients are advised to take morning medications, particularly antihypertensive medication given 
ketamine’s tendency to increase arterial pressure. Our 
list of medications that are held off from use for at least 
24 hours prior to a ketamine session include:
Lamotrigine – due to its ability to block the 
     psychological effects of ketamine
Bupropion – due to observed anxiety and mild 
     agitation during treatment 
Stimulants – for similar reasons as bupropion 
     and blood pressure elevation
These medications may be resumed later in the day after 
the treatment session concludes.
 When patients arrive there is discussion as to 
their current psychiatric status and any appropriate 
psychological assessments are completed (e.g., Beck 
Depression Inventory), though particularly anxiety-
provoking discussions are avoided. Patients are asked to 
recline and spend time deep breathing as the treatment 
is made ready and blood pressure is taken. Lights are 
dimmed and soft music is provided if the patient has 
not opted to bring their own. We remain with the 
patient monitoring status, blood pressure and safety 
considerations for 60-90 minutes during the active period 
of the treatment, and patients will spend additional time 
as needed to fully recover.
 The setting is designed to facilitate a sense of 
safety, comfort, and warmth. This is a lesson well learned 
during early studies of psychedelic psychotherapy that 
found the setting to contribute much to the effect of 
treatment. There is stark contrast between ketamine 
experienced in a florescent hospital setting surrounded 
by detached strangers with a clinical stance versus a 
warm and comfortable setting accompanied by loved 
ones. This may be in part why we rarely see anxiety 
or dysphoria to any significant degree. Patients usually 
lie quietly during the session as we sit nearby to offer 
assistance as needed. 
Monitoring and Safety During Therapy
 Ketamine produces conscious sedation within 
3-5 minutes at 0.5 mg/kg IM, which means that 
patients are responsive to verbal and physical prompts. 
Intravenous infusions over 45 minutes are associated 
with a more gradual alteration in consciousness, with 
altered awareness usually reported within 10 minutes. 
In every patient, vital signs and mental status should be 
monitored before, at least once during the session, and 
after the treatment concludes with an auto-inflatable 
pressure cuff. To reduce the incidence of nausea 
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and vomiting we recommend fasting for eight hours 
before the initial treatment, reducing to four hours for 
subsequent treatments in individuals without evidence of 
delayed gastric emptying and who establish tolerance to 
treatment side effects. Patients are advised to arrange for 
other transportation home and agree not to drive after 
treatment until they have slept a full night.   
 Some patients with controlled hypertension will 
present with elevations due to anticipatory anxiety. In 
these cases treatment is rescheduled and a prescription 
for clonidine 0.1 or 0.2 mg PO 1-2 hours before arrival 
is given. Clonidine is generally sufficient to reduce blood 
pressure within protocol range, consistent with Tanaka 
and Nishikawa (1994) who reported that administration 
of clonidine 5 mcg/kg with ketamine in full anesthesia 
abolished increases in arterial pressure seen in controls. 
While it is also possible to use propranolol in these 
situations, this may diminish the bronchodilatory effect 
of ketamine (Reich & Silvay, 1989) and thus is an inferior 
option and should not be used in patients with asthma.
 While we have not witnessed severe anxiety or 
agitation in our clinic lorazepam or alprazolam available 
for oral or IM administration is always available. 
Ondansetron 4-8 mg ODT or 2 mg liquid for IM 
injection is also available for patients who experience 
nausea despite fasting. Patients are advised to use 
acetaminophen or ibuprofen for any headaches that may 
occur after treatment. We also recommend that patients 
take 500 mg of n-acetyl cysteine (NAC) prior to arrival 
to support glutathione production.        
Dosing and Duration of Effect
 A target dose of 0.5 mg/kg IM may be initiated 
in the first session at the clinician’s discretion or the 
initial dose may be reduced by 25-50% in potentially 
sensitive individuals. The total dose many also be divided 
and separated by 10-15 minutes to reduce the speed of 
onset and peak blood levels. Some patients have required 
increased doses to improve efficacy. 
 Peak effects are felt within the first 10-20 
minutes and patients are usually mostly recovered 90 
minutes after injection. Some cognitive fog and fatigue 
may linger for some hours, or until sleep resets brain 
function.  
Beneficial Effects 
 The medical literature now provides extensive 
reports of clinical efficacy. The following are clinical 
impressions based upon a broad range of patients and 
treatment outcomes. Beneficial psychiatric effects on 
depression, anxiety, and pain are usually seen during and 
immediately following treatment, though some patients 
begin to notice effects up to 48 hours later. Patients who 
ultimately respond will almost always have a robust 
antidepressant effect with the first treatment, though 
this is not always the case.  
 In our experience, the duration of the effect 
on depression is generally from one to four weeks. For 
unclear reasons in some cases the effect fades after only a 
few days while in others it may last for months. As such, 
frequency of treatment must be adjusted to effect—
some patients only require a single session to resolve a 
depressive episode while others may require a series of 
treatments over a few weeks or months, similar to the 
frequency of acute and maintenance ECT. We generally 
treat patients once every 2-4 weeks to maintain remission 
if depression recurs, concurrently adjusting medications 
and psychotherapy to achieve a lasting remission.
 Patients with both unipolar (typical and 
atypical) and bipolar depression often respond to 
ketamine offered in our clinic. We have seen patients 
with psychotic depression improve with resolution of 
psychosis. But, we have also observed  a tendency for 
mania to become more pronounced with ketamine. 
On two occasions, we have had patients who failed to 
respond to low dose treatment go on to respond to a 
higher dose (3-8 mg/kg)  received during  an unrelated 
surgical procedure. We have repeatedly seen rapid and 
robust remission of severe suicidal ideation, consistent 
with reports from preliminary research on ketamine 
treatment (Price, Nock, Charney, & Mathew, 2009).
 It is notable that even when the strong acute 
effect on depression fades there tends to be residual 
improvement in mood that persists. In addition, we 
suspect that it is helpful for patients to experience an 
interval of recovery, however brief, after prolonged 
periods of depression. They are generally encouraged to 
know that recovery is possible. Our patients routinely 
report that ketamine provides them hope, reminding 
them what it feels like to be free of depression. 
Storage and Documention
 Ketamine and syringes for IM delivery may be 
ordered for office use through a pharmacy or a medical 
supply company. Ketamine should be stored under double 
lock-and-key as per Drug Enforcement Administration 
(DEA) regulations for in-office storage of scheduled 
medications. A log should be kept recording receipt and 
use of medication including: date, amount received, 
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amount used, amount wasted, expired medication that 
is destroyed, vial number, patient name, indication, and 
any other relevant comments. 
Towards a Mechanism of 
Action-Facilitated Emotional Learning
Enduring psychological change often requires facing emotionally painful topics, and exposure can be 
a powerful treatment technique. We have found that 
ketamine therapy facilitates this process in the days 
following treatment, when patients encounter anxiety 
cues during exposure therapy with reduced anxiety 
and defensive responses. They discuss difficult areas 
in psychotherapy with notably improved comfort and 
insight.  
 It seems likely that ketamine may intervene 
specifically at the crossroads of extinction and 
reconsolidation, two processes capable of altering the 
response to fearful memory (Centonze, Siracusano, 
Calabresis, & Bernardi, 2005; Schiller, Raio, & Phelps, 
2012; Soeter & Kindt, 2010).  
 Extinction of the response to fearful memory 
can occur through prolonged exposure within a safe 
environment. This allows a competing extinction 
memory associated with safety rather than fear to 
become associated with the trauma cues. However, short 
exposure to fearful memory can instead initiate 
reinforcement of a pathologic response through 
reconsolidation (Schiller et al., 2012). With severe 
PTSD, recall of the fearful memory during therapy often 
produces freezing and dissociation, and the resulting 
brief recall may reconsolidate and reinforce the memory, 
rather than produce extinction (Centonze et al., 2005; 
Myers, Carlezon, & Davis, 2011; Schiller et al., 2012). 
 In the days following ketamine therapy patients 
typically find it easier to discuss and encounter reminders 
of previous trauma. They do not generally experience 
the extreme anxiety and freezing produced by previous 
recall of the traumatic memory. Ketamine attenuates the 
anxiety response produced by recalling the traumatic 
memory, and thus patients engage in more extended 
discussions of the traumatic memory, potentially 
allowing for the development of extinction memory.  
A Second Mechanism of 
Action-Accelerated Self-Reliance
Treatment-resistant patients often show complex medical and psychiatric co-morbidity, social 
isolation and avoidant behaviors that point toward 
attachment difficulties. Attachment trauma, a common 
feature of PTSD (Courtois, Ford, Herman, & Van der 
Kolk, 2009), and perhaps of treatment resistant patients 
in general, inhibits recovery through its detrimental 
effects upon interpersonal intimacy and trust, self-
conception, and life-perspective. It has become clear in 
the last few decades that the neurobiological substrate of 
change through psychotherapy includes improvements 
in attachment patterns (Cozolino, 2010). 
 An important aspect of psychotherapy is 
the provision of a mature psychological model as an 
attachment structure that permits the development 
of new and secure attachment patterns within and, 
eventually, outside of the therapeutic relationship. 
The therapeutic bond acts as proxy for the patient’s 
relation to the Self (the personal and transpersonal 
subconscious—capitalized here on in the tradition of 
Jung to distinguish as the counter to ego) until authentic 
restitution can develop, bringing this process inward 
to allow a new orientation toward the outside world. 
Unfortunately, this process often advances so slowly as 
to be inconsistent with the resources of the patient. We 
have come to see ketamine treatment as an accelerant 
to this mysterious process. Perhaps through its capacity 
to engender self-acceptance, intuition, and awareness, 
patients more rapidly begin the process of relying upon 
themselves, in a deep sense, rather than the therapeutic 
bond.
Group Therapy
We provide a didactic component in a group therapy setting,  discussing topics such as 
the neurobiology of depression, pain, and anxiety, 
as well as an introduction to effective psychotherapy 
and pharmacotherapy techniques for addressing 
psychological symptoms. As an organizing principle, 
ketamine patients participating in group therapy are 
asked to focus their efforts in four areas.  
1. Automatic Scripts
The depth of each patient’s experience with 
ketamine therapy usually exposes some of the 
cognitive distortions they experience on a daily 
level. Patients often have the nature of their limited 
and disengaging programmatic scripts revealed to 
them by the experience. They may appreciate a new 
venue to consider and practice new scripts. Patients 
complete a script/schema inventory and the group 
may be educated about cognitive-behavioral links as 
leverage points for growth.  
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2. Mindfulness
Mindfulness meditation has been shown to improve 
attention and emotional self-regulation, as well 
as enhancing white matter integrity around the 
anterior cingulate gyrus, a cortical component of the 
voluntary attention system (Tang, Lu, Fan, Yang, & 
Posner, 2012; Tang & Posner, 2009). Mindfulness 
skills are an important part of effective psychotherapy 
for a broad variety of psychiatric conditions (Omidi, 
Mohammadi, Zargar, & Akbari, 2013; Teasdale, 
Segal, & Williams, 1995), and we find them helpful 
in this setting as well. We commonly use the book, 
Mindfulness: A Practical Guide to Finding Peace in 
a Frantic World (Williams & Penman, 2011) to 
educate about daily practice techniques.  In addition, 
we practice ten-minute mindfulness meditation 
techniques during the group session. 
3. Attachment / Compassion
We find that education regarding attachment theory 
can help patients identify their specific attachment 
patterns and facilitate insight-oriented change. After 
years of observing treatments with ketamine therapy, 
we believe that identifying the effect of attachment 
issues on symptoms such as depression and social 
detachment is particularly valuable. Here, we find 
discussions on compassion and the use of loving-
kindness or Metta Bhavana Meditation helpful 
(Hofmann, Grossman, & Hinton, 2011). We also 
discuss self-compassion, using exercises detailed by 
Paul Gilbert (2009) in The Compassionate Mind: A 
New Approach to Life’s Challenges.
4. Life Narrative / Mythic Reframing
Patients often experience substantial changes in 
areas such as self-concept, life goals, and personal 
understanding of life-meaning. We encourage 
discussion of authentic truth and meaning and 
support efforts to reframe major themes and 
archetypal forces within their lives. Some patients 
experience this process as occurring within a 
particular religious tradition, but others do not. 
We do not think it is the role of the therapist to 
indoctrinate patients into any particular religious 
tradition, but it is important to acknowledge the 
spiritual nature of their efforts to gain a deeper 
understanding of who they are. Ketamine permits a 
“panoramic” view of life, not only one’s own life but 
the life of others.  
Treatment Beyond Depression
Major depression is a significantly heterogeneous disorder that is often co-morbid with other 
psychiatric conditions. As such we have been able to 
observe the positive effect of ketamine upon a number 
of other disorders.   
Use in Pain
Chronic pain frequently becomes associated 
with depression and anxiety. Fortunately, ketamine 
has numerous beneficial effects on pain and many of 
our patients report that ketamine is the most effective 
treatment they have used for chronic pain. Complex 
regional pain disorder (CRPS), also known as reflex 
sympathetic dystrophy, is notoriously difficult to treat 
but sometimes responds to high-dose ketamine protocols 
offered in the United States and Germany (Schwartzmann 
et al., 2009). In five CRPS patients we have also observed 
low-dose ketamine providing noticeable acute pain 
relief. Three of these patients  gradually experienced  a 
permanent overall reduction in pain intensity over several 
months. We have seen ketamine improve chronic daily 
headaches, new daily persisting headache, neuropathic 
pain, and chronic pelvic pain.  
Use in PTSD and Anxiety Disorders
Following ketamine sessions, our patients with 
PTSD often report reduced reaction to trauma cues, with 
effects usually lasting from one to four weeks. During 
this “grace period” patients seem to be more capable of 
tolerating graded exposure. One patient, who was abused 
and tormented with rodents as a child, could not be near 
a rodent without experiencing dissociative anxiety and 
flashbacks. Following ketamine, she was able to enter a 
pet store and touch pet rats without severe anxiety. We 
have seen patients tolerate discussion of emotionally 
distressing events without feeling overwhelmed, and 
therapists often report making considerable headway in 
sessions scheduled a few days after ketamine treatment. 
Patients with social phobia and generalized anxiety 
disorder have generally reported benefits distinct from 
the antidepressant effect as well. While we have not 
treated enough patients with obsessive-compulsive 
disorder (OCD) to have an opinion, two patients with 
body dysmorphic disorders did not show any appreciable 
effect with over six sessions. 
Eating Disorders
We have observed one patient with severe mixed 
anorexia and bulimia of 12 years duration recover over 
the course of 12 months with treatments occurring 
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once per week for a total of 48 treatments. Purging and 
restriction patterns resolved completely. Psychological 
growth was demonstrated through increasingly 
meaningful and rewarding interpersonal relationships 
and an ability to tolerate a healthy romantic dyad for the 
first time. Mills, Park, Manara, and Merriman  (1998) 
reported a 70% response rate with multiple, 10 hour 
extended infusions of a low dose of ketamine in a group 
of patients hospitalized with anorexia and bulimia. 
Conclusion
Ketamine treatment shows great potential as a new pharmacological strategy in the treatment of 
depression in that it produces relief of symptoms rapidly, 
even in treatment resistant cases. Ketamine appears to 
targets the glutamatergic system that may be central to 
the neurobiology of mood disorders, and may represent 
a more direct treatment strategy than that offered by 
more conventional approaches. Its excellent safety record 
has been demonstrated over decades. Despite potential 
regulatory hurdles given that the drug cannot be patented, 
and thus poses little opportunity for pharmacological 
industry profit, the clinical observations presented here 
are offered with the hope that ketamine treatment for 
depression may find its way into more widespread use in 
outpatient settings.
Note
1.  This work was supported in part by grants from 
NARSAD and the Stanley Foundation.
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